Muddy Outcomes for MS Hookworm Therapy

Muddy Outcomes for MS Hookworm Therapy

Parasitic hookworm treatment had no important reduction on MRI in sufferers with more than one sclerosis (MS), the section II WIRMS trial showed. Median cumulative numbers of present MRI lesions had been no longer vastly diversified between MS sufferers who…

Keytruda Tops Adcetris in Head-to-Head Hodgkin’s Trial

Keytruda Tops Adcetris in Head-to-Head Hodgkin’s Trial

Pembrolizumab (Keytruda) vastly improved development-free survival (PFS) over brentuximab vedotin (Adcetris) for Hodgkin’s lymphoma sufferers who failed on or were ineligible for transplant, findings from KEYNOTE-204 confirmed. Among the 300 sufferers within the phase III trial, median PFS on blinded…